Oppenheimer Asset Management Inc. Has $1.87 Million Holdings in argenex SE $ARGX

Oppenheimer Asset Management Inc. lessened its holdings in shares of argenex SE (NASDAQ:ARGX) by 34.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,229 shares of the company’s stock after selling 1,192 shares during the period. Oppenheimer Asset Management Inc.’s holdings in argenex were worth $1,874,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of ARGX. Sound View Wealth Advisors Group LLC lifted its holdings in argenex by 3.4% in the third quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company’s stock valued at $292,000 after buying an additional 13 shares during the period. Portside Wealth Group LLC lifted its holdings in argenex by 2.8% in the third quarter. Portside Wealth Group LLC now owns 583 shares of the company’s stock valued at $430,000 after buying an additional 16 shares during the period. Harbor Investment Advisory LLC lifted its holdings in argenex by 13.9% in the fourth quarter. Harbor Investment Advisory LLC now owns 131 shares of the company’s stock valued at $110,000 after buying an additional 16 shares during the period. Cromwell Holdings LLC lifted its holdings in argenex by 10.0% in the third quarter. Cromwell Holdings LLC now owns 187 shares of the company’s stock valued at $138,000 after buying an additional 17 shares during the period. Finally, Greenleaf Trust lifted its holdings in argenex by 2.8% in the fourth quarter. Greenleaf Trust now owns 619 shares of the company’s stock valued at $521,000 after buying an additional 17 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Performance

Shares of ARGX stock opened at $811.09 on Tuesday. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62. The company has a 50-day simple moving average of $758.31 and a two-hundred day simple moving average of $818.29. The company has a market capitalization of $50.44 billion, a price-to-earnings ratio of 41.55, a PEG ratio of 1.29 and a beta of 0.46.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Saturday, February 14th. The company reported $8.02 earnings per share (EPS) for the quarter. argenex had a net margin of 30.42% and a return on equity of 38.51%. On average, sell-side analysts forecast that argenex SE will post 24.63 EPS for the current fiscal year.

Analysts Set New Price Targets

ARGX has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. Royal Bank Of Canada dropped their target price on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a report on Friday, February 27th. Wedbush restated an “outperform” rating and issued a $1,000.00 target price on shares of argenex in a report on Monday, March 9th. Truist Financial boosted their target price on shares of argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Finally, Citizens Jmp boosted their target price on shares of argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a report on Friday, February 27th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and an average price target of $1,016.22.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.